• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    FORM 8.1(a) & (b) (Opening Position Disclosure)

    11/5/25 9:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email

    DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS):

    IRISH TAKEOVER PANEL

    OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE

    1.     KEY INFORMATION

    (a) 

    Full name of discloser:

    Alkermes plc

    (b)

    Owner or controller of interests and short

    positions disclosed, if different from 1(a):

     

    The naming of nominee or vehicle

    companies is
    insufficient. For a trust, the

    trustee(s), settlor and
    beneficiaries must

    be named.

    N/A

    (c)

    Name of offeror/offeree in relation to whose

    relevant securities this form relates:

     

    Use a separate form for each offeror/offeree

    Avadel

    Pharmaceuticals 

    plc

    (d)

    Is the discloser the offeror or the offeree?

    OFFEROR

    (e) 

    Date position held:

     

    The latest practicable date prior to the

    disclosure

    3 November

    2025

    (f)  

     

    In addition to the company in 1(c) above, is

    the
    discloser also making disclosures in

    respect
    of any other party to the offer?

     

    If it is a cash offer or possible cash offer, state

    "N/A"

    N/A

    2.     INTERESTS AND SHORT POSITIONS

    If there are interests and positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

    Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates (Note 1)

    N/A

    All interests and all short positions should be disclosed.

    Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

    3.     INTERESTS AND SHORT POSITIONS OF PERSONS ACTING

            IN CONCERT WITH THE PARTY MAKING THE DISCLOSURE

    Details of any interests and short positions (including directors'

    and other employee options) of any person acting in concert with

    the party making the disclosure:

    Interests of J.P. Morgan (together with its members of staff under Rule 

    3.3(b)(v) of Part A of the Irish Takeover Rules), financial advisors to

    Alkermes plc, but, for clarity, not held on behalf of Alkermes plc:



    Party

    Class of 

    Relevant

    Security

    Number of 

    ordinary

    shares held

    at midnight

    (ET) on

    3 November

    2025

    Percentage 

    of total

    issued share

    capital

    (rounded)



    55I, LLC

    Ordinary 

    shares of

    US$0.01

    each

    53

    0.0001 %



    JPMorgan

    Chase Bank,

    National

    Association

    Ordinary 

    shares of

    US$0.01

    each

    13,500

    0.0139 %



    TOTAL



    13,553

    0.0139 %











    Details of any open stock-settled derivative positions (including traded 

    options), or agreements to purchase or sell relevant securities, should

    be given on a Supplemental Form 8.

    Ap11

    4.     OTHER INFORMATION

    (a)    Indemnity and other dealing arrangements

    Details of any indemnity or option arrangement, or any agreement

    or understanding, formal or informal, relating to relevant securities

    which may be an inducement to deal or refrain from dealing entered 

    into by the party to the offer making the disclosure or any
    person

    acting in concert with it:



    Irrevocable commitments and letters of intent should not be included. If

    there are no such agreements, arrangements or understandings, state

    "none"

     

    None

     

    (b)     Agreements, arrangements or understandings 

              relating to options or derivatives

    Full details of any agreement, arrangement or understanding

    between the person disclosing and any other person relating to the

    voting rights of any relevant securities under any option
    referred

    to on this form or relating to the voting rights or future
    acquisition

    or disposal of any relevant securities to which any
    derivative

    referred to on this form is referenced. If none, this
    should be stated. 

     

    None

     

    (c)     Attachments

    Is a Supplemental Form 8 attached?   

    YES/NO



     

     

     

    No





    Date of disclosure:

    5 November 2025

    Contact name:

    Sandy Coombs, Alkermes

    Telephone number:

    +1 781 609 6377





    Public disclosures under Rule 8.1 of the Rules must be made to a 

    Regulatory Information Service.

    Ap12

    NOTES ON FORM 8.1(a) and (b)

    1.      See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) of Part B of the Rules.



    2.      See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.



    3.      If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.



      For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.



      References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

     

    Alkermes plc Logo (PRNewsfoto/Alkermes plc)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/form-8-1a--b-opening-position-disclosure-302604930.html

    SOURCE Alkermes plc

    Get the next $ALKS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    9/26/2025$44.00Sector Perform → Outperform
    RBC Capital Mkts
    9/3/2025$44.00Overweight
    Wells Fargo
    7/15/2025$43.00Buy
    Goldman
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    3/4/2025$21.00 → $38.00Sell → Neutral
    UBS
    2/11/2025$40.00Buy
    Deutsche Bank
    More analyst ratings

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alkermes to Participate in Two Upcoming Investor Conferences

    DUBLIN, Nov. 6, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2025 Healthcare ConferenceDate/Time: Thursday, Nov. 13, 2025 at 2:40 p.m. ET (7:40 p.m. GMT) Jefferies Global Healthcare Conference in LondonDate/Time: Wednesday, Nov. 19, 2025 at 11:30 a.m. ET (4:30 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio

    11/6/25 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FORM 8.1(a) & (b) (Opening Position Disclosure)

    DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS): IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.     KEY INFORMATION (a)  Full name of discloser: Alkermes plc (b) Owner or controller of interests and short positions disclosed, if different from 1(a):   The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates:   Use a separate form for each offeror/offeree Avadel Pharmaceuticals plc (d) Is the discl

    11/5/25 9:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Reports Third Quarter 2025 Financial Results

    —    Third Quarter Revenues of $394.2 Million — —    GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 — —    Company Raises 2025 Financial Expectations — DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving strong revenue growth and robust profitability, fueled by focused execution and underlying demand across our commercial portfolio. We ended the quarter in a strong financial position and have raised our financial outlook for 2025, underscoring the momentum of the business. Our proposed acquisition of Avadel Pharmaceuticals annou

    10/28/25 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Alkermes plc

    SCHEDULE 13G - Alkermes plc. (0001520262) (Subject)

    11/10/25 8:14:11 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Alkermes plc

    10-Q - Alkermes plc. (0001520262) (Filer)

    10/28/25 9:20:51 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    10/28/25 7:05:26 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alkermes Plc upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Alkermes Plc from Sector Perform to Outperform and set a new price target of $44.00

    9/26/25 7:58:20 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Alkermes Plc with a new price target

    Wells Fargo initiated coverage of Alkermes Plc with a rating of Overweight and set a new price target of $44.00

    9/3/25 8:26:50 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Alkermes Plc with a new price target

    Goldman initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $43.00

    7/15/25 8:39:38 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP R&D, Chief Medical Officer Hopkinson Craig C. exercised 5,000 units of Ordinary Shares at a strike of $19.34 and sold $273,442 worth of Ordinary Shares (9,000 units at $30.38), decreasing direct ownership by 5% to 69,740 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    11/3/25 4:37:40 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP R&D, Chief Medical Officer Hopkinson Craig C. exercised 5,000 units of Ordinary Shares at a strike of $19.34 and sold $283,776 worth of Ordinary Shares (9,000 units at $31.53), decreasing direct ownership by 5% to 73,740 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    10/15/25 6:47:05 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, Chief Financial Officer Reed Joshua

    4 - Alkermes plc. (0001520262) (Issuer)

    10/10/25 4:41:40 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Leadership Updates

    Live Leadership Updates

    View All

    Alkermes Appoints Joshua Reed as Chief Financial Officer

    DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee. "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed.  Mr. Reed brings over 30 years of financial leadership experience, with a strong focu

    9/12/25 9:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

    DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern

    3/7/24 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    12/1/23 6:16:00 PM ET
    $ALK
    $ALKS
    $AWI
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Financials

    Live finance-specific insights

    View All

    Alkermes plc Reports Third Quarter 2025 Financial Results

    —    Third Quarter Revenues of $394.2 Million — —    GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 — —    Company Raises 2025 Financial Expectations — DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving strong revenue growth and robust profitability, fueled by focused execution and underlying demand across our commercial portfolio. We ended the quarter in a strong financial position and have raised our financial outlook for 2025, underscoring the momentum of the business. Our proposed acquisition of Avadel Pharmaceuticals annou

    10/28/25 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER RULES  —     Augments Revenue Growth Profile and Diversifies Alkermes' Commercial Portfolio with New High Growth Product, LUMRYZ™(Sodium Oxybate)—     Accelerates Alkermes' Commercial Entry into Sleep Medicine Market and Provides Strong Foundation for Potential Launch of Alixorexton—     Expected to be Immediately Accretive and Enhance Profitability Upon Closing—     Positions the Combined Organization to Accelerate Inn

    10/22/25 7:00:00 AM ET
    $ALKS
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Report Third Quarter Financial Results on October 28, 2025

    DUBLIN, Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Tuesday, Oct. 28, 2025 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.  About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap gro

    10/20/25 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alkermes plc

    SC 13G - Alkermes plc. (0001520262) (Subject)

    11/14/24 1:22:34 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/12/24 1:28:21 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/8/24 10:46:38 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care